{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"056-356-356-282-512","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"056-356-356-282-512","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11855,"type":"PATENT","title":"University of Montpellier Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11808,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8467,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
a) a yeast vehicle; and\n
b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein the HCV sequences consist of:\n\ni) an HCV NS3 protease sequence consisting of the 262 amino acids of HCV NS3 protease following the initial N-terminal 88 amino acids of full-length HCV NS3 protease (positions 1115 to 1376 with respect to SEQ ID NO:20); and\nii) an HCV Core sequence consisting of amino acid positions 2 through 140 of full-length HCV Core sequence (positions 2 to 140, with respect to SEQ ID NO:20);\n
wherein the HCV fusion protein is expressed by the yeast vehicle;\n
wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response; and\n
wherein administration of the composition to the subject reduces HCV infection or at least one symptom resulting from HCV infection in a subject."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein administration of the composition to the subject reduces HCV viral load in the subject."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein administration of the composition to the subject reduces liver damage in the subject."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to the subject at least one biological response modifier."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to the subject one or more additional compounds useful for treating or ameliorating a symptom of HCV infection."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, further comprising administering to the subject pegylated interferon-α and ribavirin."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the composition is administered by injection."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the subject is a non-responder to interferon based therapy."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the HCV Core sequence has been appended to include glutamate and aspartate."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the HCV Core sequence has been appended to include the amino acid sequence of G-G-G-H-H-H-H-H-H (SEQ ID NO:10)."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the HCV NS3 protease sequence is linked at its N-terminus to the amino acid sequence of M-A-D-E-A-P (SEQ ID NO:9)."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the expression of the fusion protein is under the control of an inducible promoter."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the yeast vehicle is a whole yeast."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the whole yeast is heat-inactivated."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein the whole yeast is from Saccharomyces cerevisiae. "],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the yeast vehicle is from Saccharomyces cerevisiae. "],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A method to reduce hepatitis C virus (HCV) infection or at least one symptom resulting from HCV infection in a subject, comprising administering to a subject a composition comprising:\n
a) a yeast vehicle; and\n
b) an HCV fusion protein consisting of SEQ ID NO:2, wherein expression of the HCV fusion protein is under the control of the promoter CUP1;\n
wherein the HCV fusion protein is expressed by the yeast vehicle; and\n
wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response;\n
wherein administration of the composition to the subject reduces HCV infection or at least one symptom resulting from HCV infection in the subject."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein administration of the composition to the subject reduces HCV viral load in the subject."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein administration of the composition to the subject reduces liver damage in the subject."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, further comprising administering to the subject at least one biological response modifier."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, further comprising administering to the subject one or more additional compounds useful for treating or ameliorating a symptom of HCV infection."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, further comprising administering to the subject pegylated interferon-α and ribavirin."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the composition is administered by injection."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the subject is a non-responder to interferon based therapy."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the yeast vehicle is a whole yeast."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 25, wherein the whole yeast is heat-inactivated."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the whole yeast is from Saccharomyces cerevisiae. "],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the yeast vehicle is from Saccharomyces cerevisiae. "],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen, comprising administering to a subject a composition comprising:\n
a) a yeast vehicle; and\n
b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein the HCV sequences consist of:\n\ni) an HCV NS3 protease sequence consisting of the 262 amino acids of HCV NS3 protease following the initial N-terminal 88 amino acids of full-length HCV NS3 protease (positions 1115 to 1376 with respect to SEQ ID NO:20); and\nii) an HCV Core sequence consisting of amino acid positions 2 through 140 of full-length HCV Core sequence (positions 2 to 140, with respect to SEQ ID NO:20);\n
wherein the HCV fusion protein is expressed by the yeast vehicle; and\n
wherein the composition elicits an HCV NS3-specific, cell-mediated immune response and an HCV Core-specific, cell-mediated immune response."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 29, wherein the yeast vehicle is a whole, heat-inactivated yeast."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 29, wherein the yeast vehicle is from Saccharomyces cerevisiae. "],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen, comprising administering to a subject a composition comprising:\n
a) a yeast vehicle; and\n
b) an HCV fusion protein consisting of SEQ ID NO:2, wherein expression of the HCV fusion protein is under the control of the promoter CUP1;\n
wherein the HCV fusion protein is expressed by the yeast vehicle; and\n
wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 32, wherein the yeast vehicle is a whole, heat-inactivated yeast."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 32, wherein the yeast vehicle is from Saccharomyces cerevisiae. "],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen in a population of individuals who have been infected with HCV, comprising administering to said population of individuals a composition comprising:\n
a) a yeast vehicle; and\n
b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein the HCV sequences consist of:\n\ni) an HCV NS3 protease sequence consisting of the 262 amino acids of HCV NS3 protease following the initial N-terminal 88 amino acids of full-length HCV NS3 protease (positions 1115 to 1376 with respect to SEQ ID NO:20); and\nii) an HCV Core sequence consisting of amino acid positions 2 through 140 of full-length HCV Core sequence (positions 2 to 140, with respect to SEQ ID NO:20);\n
wherein the HCV fusion protein is expressed by the yeast vehicle; and\n
wherein the composition elicits an HCV NS3-specific, cell-mediated immune response and an HCV Core-specific, cell-mediated immune response."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 35, wherein the yeast vehicle is a whole, heat-inactivated yeast."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 36, wherein the whole yeast is from Saccharomyces cerevisiae. "],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen in a population of individuals who have been infected with HCV, comprising administering to said population of individuals a composition comprising:\n
a) a yeast vehicle; and\n
b) an HCV fusion protein consisting of SEQ ID NO:2, wherein expression of the HCV fusion protein is under the control of the promoter CUP1;\n
wherein the HCV fusion protein is expressed by the yeast vehicle; and\n
wherein the composition elicits an HCV NS3-specific, cell-mediated immune response and an HCV Core-specific, cell-mediated immune response."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38, wherein the yeast vehicle is a whole, heat-inactivated yeast."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 39, wherein the whole yeast is from Saccharomyces cerevisiae. "],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["A method to reduce hepatitis C virus (HCV) infection or at least one symptom resulting from HCV infection in a subject, comprising administering to a subject a composition comprising:\n
a) a yeast vehicle; and\n
b) an HCV fusion protein consisting of SEQ ID NO:2;\n
wherein the HCV fusion protein is expressed by the yeast vehicle;\n
wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response; and\n
wherein administration of the composition to the subject reduces HCV infection or at least one symptom resulting from HCV infection in the subject."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 41, wherein the yeast vehicle is a whole, heat-inactivated yeast."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 42, wherein the whole yeast is from Saccharomyces cerevisiae. "],"number":43,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}